Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
Haroon Shaikh, … , Jochen Huehn, Andreas Beilhack
Haroon Shaikh, … , Jochen Huehn, Andreas Beilhack
Published October 13, 2022
Citation Information: JCI Insight. 2022;7(22):e154250. https://doi.org/10.1172/jci.insight.154250.
View: Text | PDF
Research Article Hematology Transplantation

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells

  • Text
  • PDF
Abstract

Acute graft versus host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT) inflicted by alloreactive T cells primed in secondary lymphoid organs (SLOs) and subsequent damage to aGvHD target tissues. In recent years, Treg transfer and/or expansion has emerged as a promising therapy to modulate aGvHD. However, cellular niches essential for fostering Tregs to prevent aGvHD have not been explored. Here, we tested whether and to what extent MHC class II (MHCII) expressed on Ccl19+ fibroblastic reticular cells (FRCs) shape the donor CD4+ T cell response during aGvHD. Animals lacking MHCII expression on Ccl19-Cre–expressing FRCs (MHCIIΔCcl19) showed aberrant CD4+ T cell activation in the effector phase, resulting in exacerbated aGvHD that was associated with significantly reduced expansion of Foxp3+ Tregs and invariant NK T (iNKT) cells. Skewed Treg maintenance in MHCIIΔCcl19 mice resulted in loss of protection from aGvHD provided by adoptively transferred donor Tregs. In contrast, although FRCs upregulated costimulatory surface receptors, and although they degraded and processed exogenous antigens after myeloablative irradiation, FRCs were dispensable to activate alloreactive CD4+ T cells in 2 mouse models of aGvHD. In summary, these data reveal an immunoprotective, MHCII-mediated function of FRC niches in secondary lymphoid organs (SLOs) after allo-HCT and highlight a framework of cellular and molecular interactions that regulate CD4+ T cell alloimmunity.

Authors

Haroon Shaikh, Joern Pezoldt, Zeinab Mokhtari, Juan Gamboa Vargas, Duc-Dung Le, Josefina Peña Mosca, Estibaliz Arellano Viera, Michael A.G. Kern, Caroline Graf, Niklas Beyersdorf, Manfred B. Lutz, Angela Riedel, Maike Büttner-Herold, Alma Zernecke, Hermann Einsele, Antoine-Emmanuel Saliba, Burkhard Ludewig, Jochen Huehn, Andreas Beilhack

×

Figure 3

MHCII on FRCs is dispensable for allogeneic CD4+ T cell activation during the initiation phase of aGvHD.

Options: View larger image (or click on image) Download as PowerPoint
MHCII on FRCs is dispensable for allogeneic CD4+ T cell activation durin...
(A) Experimental strategy. B6.H2-Ab1fl, B6.MHCIIΔCcl19, and B6.Ccl19.eYFP recipients were myeloablatively irradiated with 9 Gy and i.v. transplanted with 5 × 106 T cell-depleted (TCD) BM and 6 × 105 CD4+ T cells from FVB/N mice and ex vivo analyzed day 3 of allo-HCT. (B) Representative microphotographs of donor CD4+ T cells stained with CD90.1+ along with YFP expressed by SCs in B6.Ccl19-eYFP mice at day 3 of allo-HCT in LNs. (C) Normalized MFI of CD44 and CD25. (D) Frequency of Ki67+ on donor CD4+ T cells (CD90.1+CD4+) at day 3 of allo-HCT in spleen. (E) Experimental strategy. C57BL/6 (B6.WT), B6.CD11c.DOG (expressing OVA in myeloid antigen-presenting cells), and B6.iFABP-tOVA recipients (expressing OVA on FRCs and intestinal epithelial cells) were myeloablatively irradiated with 9 Gy and i.v. transplanted with 5 × 106 TCD-BM and 1 × 106 OT-II CD4+ T cells from B6.WT and B6.RagΔ.OTII.L2G85.CD45.1 mice, respectively, and analyzed on day 3 of syn-HCT. (F) Ex vivo bioluminescence imaging (BLI) micrograph. (G) CFSE dilution on adoptively transferred CD4+CD45.1+ T cells in mLNs. (H) Quantification of the adoptively transferred OT-II T cells (CD45.1+CD4+) BLI signal and CFSE dilution in mLNs on day 3 of syn-HCT. Data were pooled from 2 experiments, with 1 data point representing 1 mouse. Two-way ANOVA with Tukey’s test was used; data are shown as mean± SD. ***P < 0.001 and ****P < 0.0001. (I) Survival of myeloablatively irradiated (9 Gy) B6.H2-Ab1fl and B6.MHCIIΔCcl19 mice transplanted with 5 × 106 TCD-BM and 6 × 105 enriched CD4+ T cells from FVB/N mice illustrated in Kaplan-Meier curve.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts